secwatch.observer — SEC 8-K summary
======================================

Issuer:     Disc Medicine, Inc. (IRON)
CIK:        0001816736
Form:       8-K
Filed at:   2023-06-09T23:59:59+00:00
Accession:  0001193125-23-164010
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Disc Medicine reports positive Phase 2 bitopertin data in EPP: PPIX down >40%, sunlight tolerance up >80-fold
--------------------------------------------------------------------------------

- Mean reduction of whole-blood PPIX >40% in dose-dependent, sustained manner across 15 patients.
- Two patients with longest follow-up: >80-fold (20 mg) and >200-fold (60 mg) increase in sunlight tolerance without prodrome.
- Average weekly sunlight exposure rose from 344 min at baseline to 1,200 min at Week 24; time to prodrome increased >7-fold.
- Patient-reported phototoxic reactions reduced 96% vs. baseline; all 10 patients at Day 43 reported disease much/a little better on PGIC.
- Bitopertin well-tolerated: no serious AEs, no discontinuations, no grade >1 AEs, no meaningful hemoglobin changes.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1816736/000119312523164010/0001193125-23-164010-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1816736/000119312523164010/d350054d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-164010

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer